Today, a brief rundown of news from Halozyme Therapeutics and Cytokinetics, as well as updates from Boehringer Ingelheim, GSK and Epidarex Capital that you may have missed.

Alongside an announcement about its financial guidance, Halozyme Therapeutics on Wednesday revealed that it acquired privately held drug delivery specialist Surf Bio. Halozyme is paying $300 million upfront and potentially $400 million overall for Surf, which has a technology that enables multiple drug types to be quickly delivered via high-concentration, subcutaneous injections. That technology is being used across a “wide range of therapeutic areas,” Halozyme said. The deal should enhance the company's long-term growth prospects, wrote Leerink Partners analyst David Risinger. — Ben Fidler

Cytokinetics on Tuesday officially launched in the U.S. its drug Myqorzo for people with symptomatic obstructive hypertrophic cardiomyopathy, an inherited form of heart failure. Myqorzo, which was approved by regulators last month, will compete for market share with Bristol Myers Squibb’s Camzyos, a similar type of medicine that was on track to top $1 billion in sales last year. At a conference earlier this month, Cytokinetics revealed Myqorzo will have a yearly per-patient list price of $108,400. That price equates to “parity-slight-plus” compared to Camzyos, as the company is “not so much competing on price,” but “on the clinical and physician patient experience,” CEO Robert Blum said at the meeting. A yearly supply of Camzyos has a current wholesale acquisition cost of about $104,800. — Ben Fidler

Boehringer Ingelheim grabbed partial rights to an experimental inflammatory bowel disease drug discovered by Nanjing, China-based Simcere Pharmaceutical Group. The companies didn’t specify in a Tuesday statement how much Boehringer is paying in guaranteed upfront cash, but Simcere could receive a total of about 1.06 billion euros, or $1.27 billion, in payouts if the drug hits a variety of targets. Simcere’s drug is a bispecific antibody aimed at TL1A and IL-23, both well-known targets in IBD. Startup Caldera Therapeutics is pursuing a similar strategy via a licensing deal with a different Chinese drugmaker. — Ben Fidler

The European Commission on Monday broadened use of GSK’s RSV vaccine, clearing the shot for use in adults aged 18 and older. In Europe, the shot, known as Arexvy, was previously only allowed in adults aged 60 years and older, as well as in people between 50 and 59 who are at high risk of severe disease. The new approval adds to an edge for Arexvy, which has had a dominant market presence over rival shots from Pfizer and Moderna. GSK is working to widen use in other areas, including Japan and the U.S. — Delilah Alvarado

Epidarex Capital, a life sciences venture firm, announced Tuesday it closed $145 million in funding to build drug or medical device startups from research in the U.S. and U.K. The investor, which previously backed companies like Apellis Pharmaceuticals and NodThera, plans to lead early-stage financings and distribute the capital among as many as 15 startups. Its backers include British Business Bank, Strathclyde Pension Fund and the Scottish National Investment Bank. — Gwendolyn Wu